ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company, has announced its financial results for the year ended December 31, 2025, alongside significant updates on its clinical trials. The company reported a net loss of $39.7 million, reflecting its ongoing investment in the PRECISE-AD Phase 1b clinical trial for Alzheimer's disease. The trial, which focuses on the company's lead candidate PMN310, has successfully completed enrollment with 144 participants, exceeding the initial target of 128. This oversubscription indicates strong interest in PMN310's therapeutic potential. The company is on track to complete six-month assessments in Q2 2026, with an interim analysis expected in early Q3 2026 and top-line data anticipated in early 2027. PMN310 has demonstrated a favorable safety profile, with no treatment-related serious adverse events reported to date. In early 2026, ProMIS secured a transformational financing of up to $175 million, which includes $75 million upfront and $100 million tied to future potential exercise of warrants. This funding is expected to provide a cash runway through 2027, allowing the company to accelerate the development of PMN310 and its next clinical study. The company remains optimistic about the potential of PMN310 to address the underlying pathology of Alzheimer's disease, particularly given its Fast Track designation from the FDA. ProMIS is also exploring the development of a subcutaneous formulation of PMN310, which could enhance patient experience and strengthen the asset's competitive profile. Overall, the company's strategic outlook remains positive as it continues to advance its clinical programs and explore new opportunities in the neurodegenerative disease space.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.